FIG. 5.

cART NPs efficacy in HIV-1-infected cells in vitro. Supernatants (A) and cell lysates (B) were analyzed by western blot with anti-Gag and anti-GAPDH antibodies as indicated. SupT1 T cells were infected with HIV-1 NLX and treated with 0.05 mg/ml at the same time for 24 h. After extensive washing the cells were incubated for an additional 48 h, and the cell supernatants and lysates were harvested. (C) TZM-bl reported cells were inoculated with HIV-1+VSVg and the next day treated with 0.05 mg/ml of either cART or blank NPs. After 48 h, the cells were lysed and assayed for luciferase expression using a luminometer and reported as relative light units (RLU). A significant (p<0.001) reduction for cART NPs was observed. Data represent the mean of eight individual infects and error bars represent standard error of the mean. (D) TZM-bl cells were treated with six 10-fold dilutions of cART and the next day inoculated with HIV-1 NLX. After 48 h, the cells were lysed and luciferase assays were performed. RLU values were obtained with a luminometer. Data are representative of triplicate samples. Error bars denote standard error of the mean.